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A case of a 50-year-old woman who was referred for the evaluation of possible ACTH-dependent Cushing’s syndrome (CS) is 
described. The localisation of ACTH-dependent CS remains difficult despite many advances in diagnostic approaches. No single 
test can accurately determine the location of ACTH excess and therefore a combination of non-invasive imaging, stimulation and 
suppression tests are advised. The recent advances, current utility and pitfalls of each of these tests are reviewed. If non-invasive 
tests fail to confidently localise the source of ACTH excess, inferior petrosal sinus sampling (IPSS) should follow. Recent advances 
improving the diagnostic accuracy of IPSS, such as DDAVP stimulation and simultaneous sampling for prolactin is discussed. 
Where ectopic ACTH production is suspected, newer nuclear medicine techniques, such as somatostatin receptor imaging that 
recently became available in South Africa, can be utilised. The role of nuclear medicine imaging in identifying ectopic ACTH 
production is discussed briefly.
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Case presentation
A 50-year-old obese woman was referred to the division of 
Endocrinology at Tygerberg Hospital for the evaluation of 
possible Cushing’s syndrome (CS). She had been diagnosed with 
diabetes mellitus and hypertension in the preceding year and 
noted unexplained marked weight gain, in excess of 12 kilograms 
in three months. She had no history of alcohol abuse or 
depression and took no medication apart from anti-hypertensives 
and oral anti-diabetes drugs. On examination she was morbidly 
obese with a BMI of 43 kg/m2. She had thin skin, violaceous striae 
and facial plethora. On bone mineral density assessment she had 
osteoporosis most markedly in her lumbar spine. Her serum 
cortisol failed to suppress on an overnight 1 mg betamethasone 
test (444 nmol/L). Twenty-four hour urine free cortisol was also 
elevated (1356 nmols/24 hours) and her serum cortisol failed to 
suppress on prolonged low-dose betamethasone testing (0.5 mg 
12 hourly for 48 hours). Adrenocorticotrophic hormone (ACTH) 
was 9.3 pmol/L (normal 1.1–10.2 pmol/L).
Background
The diagnosis of CS remains difficult despite many advances in 
diagnostic approaches. The difficulties lie in both the functional 
demonstration and the localisation of hormonal overproduction. 
Apart from the problem of differentiating true CS from pseudo-
Cushing’s, ACTH-dependent CS also poses a particular diagnostic 
challenge.
In approximately 40% of cases, ACTH-producing pituitary 
adenomas in pituitary Cushing’s disease (PC) are not visualised 
on magnetic resonance imaging (MRI) of the pituitary.1 Moreover, 
non-functioning pituitary microadenomas may occur in up to 
10% of the general population.2 Thus, in patients with ectopic 
ACTH producing tumours (EC), an incidental finding of a pituitary 
microadenoma (which may falsely attribute the source of ACTH 
production to the pituitary) is not uncommon.3 Therefore, 
isolated MRI findings of either the absence or presence of a 
pituitary microadenoma is of little value without biochemical 
evidence in support of the MRI findings.
Testing in ACTH-dependent CS is problematic, considering that 
PC is by far the most common aetiology of CS. The pre-test 
probability for PC is about 80–90%.4 Therefore any test that 
differentiates PC from EC needs to be very accurate to improve 
on the pre-test probability of PC. Inferior petrosal sinus sampling 
(IPSS) remains the most accurate method to localise the source 
of ACTH excess.5,6 However, IPSS is invasive with a risk of adverse 
events and requires expertise that is not readily available, 
especially in South Africa. Unfortunately no non-invasive test, 
when used in isolation, can improve on the aforementioned pre-
test probability for PC. As a result, a three-pronged testing 
approach has been proposed in subjects with ACTH-dependent 
Cushing’s syndrome, prior to proceeding to IPSS.4,6
First, MRI of the pituitary should be performed. This should be 
followed by a high dose dexa(beta)methasone suppression test 
(HDDST). Third, a stimulation test using either corticotropin 
releasing hormone (CRH) or desmopressin (DDAVP) should be 
performed. If an adenoma of more than 6  mm (based on 
consensus recommendation)1 is demonstrated and the results of 
the suppression and stimulation tests are concordant and in 
keeping with a pituitary source of ACTH overproduction, the 
diagnosis of PC is made and surgery can be recommended 
without IPSS. However, if any of the three criteria (positive 
imaging, suppression test and stimulation test) are not met, 
invasive testing by means of IPSS should follow. Should IPSS not 
suggest PC, further imaging to localise EC should ensue. 
The page number in the footer is not for bibliographic referencingwww.tandfonline.com/oemd 21
JEMDSA
ISSN 1608-9677   EISSN 2220-1009
© 2016 The Author(s)
RESEARCH
Journal of Endocrinology, Metabolism and Diabetes of South Africa 2016; 21(3):47–50
http://dx.doi.org/10.1080/16089677.2016.1212965
Open Access article distributed under the terms of the
Creative Commons License [CC BY-NC 3.0]
http://creativecommons.org/licenses/by-nc/3.0
Journal of Endocrinology, Metabolism and Diabetes of South Africa is co-published by Medpharm Publications, NISC (Pty) Ltd and  
Taylor & Francis, and Informa business.
Latest diagnostic approaches to determine the cause of ACTH-dependent 
Cushing’s syndrome, in the South African setting
Elmo Pretoriusa*, Razaan Davisb, Alexander Doruyterc and Brynne Ascott-Evansa
a Faculty of Medicine and Health Sciences, Division of Endocrinology, Department of Medicine, Stellenbosch University and Tygerberg Academic 
Hospital, Cape Town, South Africa
b Faculty of Medicine and Health Sciences, Division of Radiodiagnosis, Department of Medical Imaging and Clinical Oncology, Stellenbosch 
University and Tygerberg Academic Hospital, Cape Town, South Africa
c Faculty of Medicine and Health Science, Division of Nuclear Medicine, Department of Medical Imaging and Clinical Oncology, Stellenbosch 
University and Tygerberg Academic Hospital, Cape Town, South Africa
*Corresponding author, email: elmo@sun.ac.za
A case of a 50-year-old woman who was referred for the evaluation of possible ACTH-dependent Cushing’s syndrome (CS) is 
described. The localisation of ACTH-dependent CS remains difficult despite many advances in diagnostic approaches. No single 
test can accurately determine the location of ACTH excess and therefore a combination of non-invasive imaging, stimulation and 
suppression tests are advised. The recent advances, current utility and pitfalls of each of these tests are reviewed. If non-invasive 
tests fail to confidently localise the source of ACTH excess, inferior petrosal sinus sampling (IPSS) should follow. Recent advances 
improving the diagnostic accuracy of IPSS, such as DDAVP stimulation and simultaneous sampling for prolactin is discussed. 
Where ectopic ACTH production is suspected, newer nuclear medicine techniques, such as somatostatin receptor imaging that 
recently became available in South Africa, can be utilised. The role of nuclear medicine imaging in identifying ectopic ACTH 
production is discussed briefly.
Keywords: ACTH, cushing’s disease, pituitary
Case presentation
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noted unexplained marked weight gain, in excess of 12 kilograms 
in three months. She had no history of alcohol abuse or 
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and oral anti-diabetes drugs. On examination she was morbidly 
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12 hourly for 48 hours). Adrenocorticotrophic hormone (ACTH) 
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Background
The diagnosis of CS remains difficult despite many advances in 
diagnostic approaches. The difficulties lie in both the functional 
demonstration and the localisation of hormonal overproduction. 
Apart from the problem of differentiating true CS from pseudo-
Cushing’s, ACTH-dependent CS also poses a particular diagnostic 
challenge.
In approximately 40% of cases, ACTH-producing pituitary 
adenomas in pituitary Cushing’s disease (PC) are not visualised 
on magnetic resonance imaging (MRI) of the pituitary.1 Moreover, 
non-functioning pituitary microadenomas may occur in up to 
10% of the general population.2 Thus, in patients with ectopic 
ACTH producing tumours (EC), an incidental finding of a pituitary 
microadenoma (which may falsely attribute the source of ACTH 
production to the pituitary) is not uncommon.3 Therefore, 
isolated MRI findings of either the absence or presence of a 
pituitary microadenoma is of little value without biochemical 
evidence in support of the MRI findings.
Testing in ACTH-dependent CS is problematic, considering that 
PC is by far the most common aetiology of CS. The pre-test 
probability for PC is about 80–90%.4 Therefore any test that 
differentiates PC from EC needs to be very accurate to improve 
on the pre-test probability of PC. Inferior petrosal sinus sampling 
(IPSS) remains the most accurate method to localise the source 
of ACTH excess.5,6 However, IPSS is invasive with a risk of adverse 
events and requires expertise that is not readily available, 
especially in South Africa. Unfortunately no non-invasive test, 
when used in isolation, can improve on the aforementioned pre-
test probability for PC. As a result, a three-pronged testing 
approach has been proposed in subjects with ACTH-dependent 
Cushing’s syndrome, prior to proceeding to IPSS.4,6
First, MRI of the pituitary should be performed. This should be 
followed by a high dose dexa(beta)methasone suppression test 
(HDDST). Third, a stimulation test using either corticotropin 
releasing hormone (CRH) or desmopressin (DDAVP) should be 
performed. If an adenoma of more than 6  mm (based on 
consensus recommendation)1 is demonstrated and the results of 
the suppression and stimulation tests are concordant and in 
keeping with a pituitary source of ACTH overproduction, the 
diagnosis of PC is made and surgery can be recommended 
without IPSS. However, if any of the three criteria (positive 
imaging, suppression test and stimulation test) are not met, 
invasive testing by means of IPSS should follow. Should IPSS not 
suggest PC, further imaging to localise EC should ensue. 
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However, where clinical and/or biochemical features strongly 
point to EC as the potential cause, imaging to localise the EC 
source may be appropriate, before deciding if IPSS is still indicated.
Magnetic resonance imaging
Dynamic contrast-enhanced (DCE) thin section (3  mm) T1-
weighted (T1  W) MRI is the imaging technique of choice for 
diagnosing pituitary microadenomas. The evaluation of areas of 
differential enhancement within the pituitary gland, following 
the administration of a gadolinium-based contrast agent, allows 
for improved diagnostic accuracy of small lesions. Section-
selective T1  W turbo spin echo (TSE) sequences are compared 
before and at multiple time points after the administration of 
contrast.7 Imaging is usually performed in a coronal plane, but 
sensitivity is increased by employing a combination of sagittal 
and coronal planes.8,9 Conventional T1 W and T2 W SE sequences 
in combination with DCE T1  W detect the microadenoma in 
approximately 70% of cases and improve on sensitivity in 
comparison with conventional MRI alone.10,11 Limitations of DCE 
scanning include difficulty in distinguishing between a simple 
cyst and a microadenoma as well as the non-standardised 
dynamic image acquisition time frame.7 In our patient, utilising 
DCE, a vague 5 mm hypodensity in the right pituitary could be 
demonstrated.
High dose dexa(beta)methasone suppression 
test
HDDST is a simple and non-invasive test that can be performed 
without sophisticated equipment or expertise. When compared 
directly, at similar specificities of nearly 100% each, the 8  mg 
overnight dexamethasone suppression test has a sensitivity of 
71% compared with 65% for the prolonged high-dose 
dexamethasone suppression test.12,13 Due to the better sensitivity, 
simplicity and shorter duration, the overnight test should be the 
preferred test. Unfortunately, oral dexamethasone is no longer 
registered for in use in South Africa and is only obtainable on a 
patient-named basis through the Medicines Control Council. To 
our knowledge there are no studies comparing dexamethasone 
and betamethasone in this context. However, betamethasone 
has been previously shown to have a similar traditional 
pharmacokinetic and potency profile to dexamethasone and, as 
such, is deemed to be a suitable alternative to dexamethasone.14
It is accepted that a small proportion of pituitary adenomas do 
not suppress whilst a proportion of ectopic ACTH-producing 
tumours can exhibit a degree of suppression with HDDST. Various 
cut-off values to predict PC have been proposed, ranging from 
50–80% suppression of serum cortisol from baseline.1 It is evident 
that specificity is enhanced (at the expense of sensitivity) by 
increasing the cut-off percentage value for suppression. There is 
uncertainty as to the optimal cut-off value and opinions vary 
regarding the usefulness of this test.15 However, the role of HDDST 
in the proposed approach is not to act as a single diagnostic test, 
but rather to rule in PC in concordance with MRI findings (and 
ACTH stimulation) and therefore avoid invasive IPSS prior to 
pituitary surgery. At our centre we use a cut-off value of greater 
than 68% suppression of serum cortisol, which has been shown 
to translate into a specificity of nearly 100%.13 In our patient, 
serum cortisol was suppressed by 89% on HDDST, which strongly 
suggests PC.
CRH and DDAVP stimulation tests
The CRH stimulation test has been extensively studied using 
various cut-off criteria of either increments of ACTH or cortisol, 
various doses of CRH, varying time intervals of sampling, as well 
as using either human or ovine CRH. With sensitivities and 
specificities reported in the range of 90%, this test is the most 
accurate non-invasive test. There is, however, no consensus with 
regard to optimal methodology and diagnostic criteria for this 
test.6,16 Furthermore, CRH is not freely available in South Africa 
and is only obtainable at great cost and effort. As such, the CRH 
stimulation test, although useful, has limited application in our 
setting.
Receptors for vasopressin (AVP) are found on corticotrophs. 
Although initial studies indicated DDAVP stimulation to be useful 
in differentiating pituitary from ectopic ACTH overproduction, it 
has been shown that many ectopic sources also express 
vasopressin receptors, and may respond to DDAVP stimulation. 
Thus, when used in isolation, the DDAVP stimulation test performs 
poorly in differentiating ectopic from pituitary ACTH production.17 
However, DDAVP is freely available in South Africa and a 
concordant DDAVP test adds to diagnostic accuracy for PC when 
used in combination with other positive tests.18 As our patient did 
not demonstrate a more than 6 mm pituitary lesion on MRI, which 
was discordant with the pronounced pituitary localisation on 
HDDST, we proceeded to perform IPSS without a DDAVP 
stimulation test. If MRI and HDDST are discordant (as was the case 
in our patient), IPSS is inevitable and a DDAVP stimulation test 
before proceeding to IPSS will add no further diagnostic value.
Inferior petrosal sinus sampling
Data from multiple studies estimates specificity for PC at 90–95%, 
when a central inferior petrosal sinus (IPS) to peripheral ACTH 
ratio of greater than 2:1 is used to localise the source.5 Sensitivity 
of IPSS for PC has been reported with much greater variability 
(54–96%), but most studies report sensitivities well above 80%.5 
Our patient had a ratio of 12:1 from the right IPS, which far 
exceeds this diagnostic threshold and confirms PC. Of note, 
samples taken from the left IPS showed ACTH concentrations 
equal to peripheral blood, at a ratio of 1:1 (see below).
CRH stimulation has been shown to exaggerate the central to 
peripheral ACTH ratio. By using a ratio of greater than 3:1 with 
CRH stimulation during IPSS, most studies report an increased 
accuracy, especially with regard to an improvement in the 
sensitivity to 81–100%.5 However, as discussed earlier, CRH is 
largely unobtainable in South Africa.
More recently DDAVP stimulation during IPSS has been utilised 
with comparable enhancement of diagnostic accuracy, as seen 
with CRH stimulation using the same central to peripheral ratio of 
3:1. A sensitivity of 92–95% and specificity of 100% have been 
reported in two case series.19,20 Although side effects are rare, 
DDAVP administration does have the potential for 
vasoconstriction, hyponatraemia and haemostatic effects for 
which patients should be observed after the procedure.5 Due to 
the invasive nature of IPSS, diagnostic accuracy should be 
enhanced in every feasible way and, as such, DDAVP is a suitable 
alternative to CRH in the South African setting during IPSS. In our 
patient the central to peripheral ACTH ratio in the right catheter 
doubled to 24:1 after 10 mcg DDAVP IV administration.
IPSS is a technically demanding procedure fraught with possible 
error. Despite confirming correct anatomical placement 
radiologically before the procedure, sampling from the inferior 
petrosal sinuses may not be accurate. Various factors may 
contribute such as displacement of catheters during sampling, 
uneven rate of sampling between left and right (blood may be 
shunted away from one side to the other if aspiration is done too 
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vigorously) or anomalous venous drainage of non-pituitary blood 
to the IPS.21,22 If any of these factors is present, it is unlikely to be 
noted during the sampling procedure.
Prolactin measurements during IPSS have recently been 
introduced to overcome the uncertainty as to whether IPS blood 
was accurately sampled, in cases where IPSS does not confirm a 
pituitary source of ACTH overproduction. Although prolactin 
measurements cannot confirm correct sampling timeously 
during the procedure, analysis post-hoc avoids unnecessary 
investigation for an ectopic source of ACTH production in such 
cases. If blood sampled from one or both IPS does not show an 
elevated prolactin level compared with peripheral blood, it may 
be assumed that the IPS was not accurately sampled and IPSS 
may need to be repeated. A central to peripheral prolactin ratio of 
greater than 1.8:1 is considered to indicate appropriate IPSS.23–27 
In our case the central to peripheral IPS prolactin ratio at baseline 
was 1:1 in the left compared with 3:1 for the right IPS. This signifies 
that the left IPS essentially sampled peripheral blood. This 
explains the low peripheral to left ACTH ratio, and invalidates all 
results from the left IPS.
Another use of prolactin measurement during IPSS (with or 
without CRH or DDAVP stimulation) is correcting ACTH levels for 
prolactin where ACTH levels alone were not convincingly 
diagnostic. Blood sampled from the IPS may be diluted by blood 
draining from sites other than the pituitary and therefore disturb 
the central to peripheral ACTH ratio. However, it can be assumed 
that a proportionate dilution will also occur with prolactin 
measurement. Prolactin can therefore be used to ‘correct’ ACTH 
for this dilutional effect. Prolactin-corrected ACTH peripheral to 
IPS ratios are determined by the highest ACTH central to 
peripheral ratio divided by the concurrent and ipsilateral prolactin 
central to peripheral ratio. A prolactin-corrected ACTH central to 
peripheral ratio of greater the 1.2:1 is diagnostic of PC.28 Using the 
prolactin correction additional cases of PC could be correctly 
detected, without decreasing the specificity.23–27 This may avoid 
an unnecessary repeat of IPSS.
In PC, IPSS lateralisation of a microadenoma to either the left or 
right pituitary remains almost equal to chance, despite stimulation 
with either DDAVP or CRH.5,19 It has, however, been shown that 
correction of ACTH ratios for prolactin improves the accuracy of 
localisation.27,28 Right and left ACTH levels are corrected for 
prolactin levels by dividing the ACTH level by the ipsilateral and 
concurrent prolactin value. If the ratio of these prolactin-corrected 
ACTH values between right and left IPSS is greater than 1.4:1, the 
source may be lateralised accurately in 75–77% of cases, and 82–
100% when lateralisation on MRI is concordant.27,28 Although 
preoperative lateralisation does not substitute for intraoperative 
visualisation of the tumour by the surgeon, it does assist in 
minimising exploration and pituitary damage if a probable site of 
the tumour is determined beforehand.
Localisation of an ectopic source of ACTH 
production
Multiple imaging modalities are available to evaluate the source 
of EC, if appropriately performed IPSS and its interpretation 
suggests a non-pituitary source of ACTH production. Recently a 
large systematic review was published on this topic.29 Key findings 
were that in more than half of the cases of EC the disease was 
overt and detectable by conventional radiology alone (whole-
body computerised tomography [CT] and MRI). However, both 
false positives and negatives occurred, using conventional 
radiology. It is therefore recommended that should a tissue 
diagnosis not be confirmatory after localisation with conventional 
radiology, nuclear medicine imaging should ensue: either 
somatostatin receptor imaging (e.g.99mTc-HYNIC octreotide 
SPECT/CT; 68 Ga-DOTANOC PET/CT); or using a glucose analogue 
— 18F-fluorodeoxyglucose (FDG) PET/CT. Imaging of amino acid 
metabolism with 18F-DOPA PET/CT may also be considered where 
available.
For covert disease where both MRI and CT scan failed to detect 
the source of EC, PET/CT using 68  Ga-DOTA-labelled octreotide 
analogues had the best sensitivity of close to 100%. This modality 
has recently become available in the public sector in South Africa 
and is a valuable tool in this context. It is also cheaper than 
comparable SPECT agents. It must, however, be highlighted that 
when used as a first-line test for locating the source of any EC 
(including overt disease), Gallium PET/CT performed inferiorly 
compared with conventional radiology. Therefore Gallium PET/CT 
should ideally only be utilised after CT or MRI, either to confirm a 
lesion detected on either of these modalities, or as a second- (or 
third-) tier investigation to confirm an abnormal finding, when 
doubt remains after anatomical imaging. It should also be noted 
that in more than 18% of cases of EC, the source will remain 
occult, despite utilising multiple imaging modalities. In such 
cases periodic reimaging should follow or the diagnosis of PC 
should be reconsidered.
An algorithm for the work-up of ACTH-dependent CS is suggested 
in Figure 1. However, many factors may influence the decision on 
the most appropriate modalities to be used including the patient’s 
clinical condition and presentation, local availability of nuclear 
medicine imaging techniques and cost. Decisions should be 
preferably be made by a multidisciplinary team consisting of 
endocrinologists, radiologists, nuclear medicine physicians and 
neurosurgeons.
Figure 1: Suggested approach to the diagnostic workup of ACTH-
dependent Cushing’s syndrome.
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Conclusion
This case illustrates some of the difficulties in the diagnosis of ACTH-
dependent CS. Despite the low availability of CRH in South Africa, we 
are still able to utilise many of the most modern diagnostic 
approaches, including DCE-MRI, IPSS with ACTH and prolactin 
sampling and DDAVP stimulation. More recently, locally available 
nuclear medicine techniques (such as PET/CT with 68 Ga-DOTANOC or 
equivalent) now allow covert, complicated cases of ACTH-dependent 
CS to be confidently and competently managed in South Africa.
Returning to our patient: at surgery a microadenoma was removed 
from the right side of the pituitary, which stained strongly for ACTH. 
However, following the surgery there was no clinical or biochemical 
evidence of cure. A second, more aggressive, transsphenoidal 
resection was performed. On follow-up she lost 20 kg in mass was 
normotensive and euglycaemic off all medication, and suppressed 
to 58 nmol/L on a betamethasone suppression test.
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